Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Intas Pharma

Teva Pharma logo

Teva launches first inhaled antipsychotic in US

Adasuve available for the treatment of agitation associated with schizophrenia or bipolar disorder

- PMLiVE

Novartis to close UK R&D site

Research operations at Horsham expected to end in June

- PMLiVE

FDA expands efforts to test quality of generics

Monitoring programme to ensure drug copies are equivalent to branded medicines

- PMLiVE

Teva’s Symbicort generic backed for EU approval

AstraZeneca braces for competition to COPD drug

- PMLiVE

Actavis acquires Forest for $25bn

Ramps up its shift into speciality pharmaceuticals

- PMLiVE

Actavis ‘negotiating $25bn acquisition’ of Forest

Generic company reportedly in late-stage takeover talks

Deal Watch table for January 2014

Table listing all the major pharma mergers, acquisitions and collaborations in the past month

Pharma deals during January 2014

Deal Watch: Major pharma collaborations, acquisitions and agreements in the past month

- PMLiVE

Teva faces US marketing investigation

Department of Justice to probe promotion tactics for Copaxone and Azilect

UK flag

UK plans to reduce use of animals in research

Looks to new technologies to screen earlier for drug failures

- PMLiVE

CHMP turns down drugs for MS, cancer and muscular dystrophy

Negative EU recommendations for Teva, AB Science and PTC Therapeutics

China flag thumb

Actavis divests another Chinese interest

Reduces presence in “risky” market

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links